期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Serum cytokine levels in patients with advanced non-small cell lung cancer： correlation with clinical outcome of erlotinib treatment 被引量：2

Serum cytokine levels in patients with advanced non-small cell lung cancer： correlation with clinical outcome of erlotinib treatment
原文传递
导出
摘要 Background Serum expression of cytokines may provide information about the clinical outcome of advanced non-small cell lung cancer （NSCLC） patients. This study aimed to investigate the relationship between serum cytokine levels and the clinical outcome of erlotinib treatment in a second or third line setting in patients with advanced NSCLC. Background Serum expression of cytokines may provide information about the clinical outcome of advanced non-small cell lung cancer （NSCLC） patients. This study aimed to investigate the relationship between serum cytokine levels and the clinical outcome of erlotinib treatment in a second or third line setting in patients with advanced NSCLC.
作者 Wang Yong-sheng Miao Li-yun Liu Lu Cai Hou-rong Ding Jing-jing Ren Sheng-xiang Zhou Cai-cun Schmid-Bindert, Gerald
机构地区 Nanjing Univ Tongji Univ Tongji Univ Heidelberg Univ
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2013年第20期3931-3935,共5页 中华医学杂志（英文版）
关键词 lung cancer erlotinib serum cytokine clinical outcome lung cancer, erlotinib serum cytokine, clinical outcome
分类号 S852.43 [农业科学—基础兽医学] S852.4 [农业科学—基础兽医学]
  • 相关文献

参考文献26

  • 1Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
  • 2Gately K, O'Flaherty J, Cappuzzo F, Pirker R, Kerr K, O'Byme K. The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC. J Clin Pathol 2012; 65: 1-7.
  • 3Socinski MA, Crowell R, Hensing TE, Langer C J, Lilenbaum R, Sandier AB, et al. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2rid edition). Chest 2007; 132 (3 Suppl): 277S-289S.
  • 4Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith T J, Baker S, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22: 330-353.
  • 5Gridelli C, Ardizzoni A, Ciardiello F, Hanna N, Heymach JV, Perrone F, et al. Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol 2008; 3: 430-440.
  • 6Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small- cell lung cancer. N Engl J Med 2005; 353: 123-132.
  • 7Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small- cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129- 2139.
  • 8Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
  • 9Cataldo VD, Gibbons DL, Perez-Soler R, Quintas-Cardama A. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med 2011; 364: 947-955.
  • 10Zhou S, Ren S, Yan L, Zhang L, Tang L, Zhang J, et al. Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer. Respirology 2009; 14: 709-715.

同被引文献16

引证文献2

二级引证文献3

Chinese Medical Journal
2013年 第20期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部